Ultragenyx Pharmaceutical Inc.
NASDAQ: RARE0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Select
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Emil D. Kakkis
- Employees
- 1,294
- Headquarters
- Novato, United States
- IPO year
- 2014
- Market cap
- $2.7B
- Website
- https://www.ultragenyx.com
Loading RARE…
Loading profile data…Frequently asked questions about RARE
What does Ultragenyx Pharmaceutical Inc. (RARE) do?
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases...
Where does RARE trade?
Ultragenyx Pharmaceutical Inc. (RARE) trades on the NASDAQ Global Select.
What sector is RARE in?
Ultragenyx Pharmaceutical Inc. (RARE) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Ultragenyx Pharmaceutical Inc.?
Emil D. Kakkis is the chief executive officer of Ultragenyx Pharmaceutical Inc. (RARE).
Where is Ultragenyx Pharmaceutical Inc. headquartered?
Ultragenyx Pharmaceutical Inc. is headquartered in United States.
Does RARE pay a dividend?
Ultragenyx Pharmaceutical Inc. (RARE) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RARE go public?
Ultragenyx Pharmaceutical Inc. (RARE) completed its initial public offering in 2014.